HUA MEDICINE (SHANGHAI) LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.62 HKD | +1.89% |
|
+7.28% | -17.77% |
| Mar. 28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
| Sales 2023 | 76.61M 10.57M 82.79M | Sales 2024 * | 594M 82.03M 642M | Capitalization | 1.44B 199M 1.56B |
|---|---|---|---|---|---|
| Net income 2023 | -211M -29.12M -228M | Net income 2024 * | -233M -32.16M -252M | EV / Sales 2023 | 22.9 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 2.42 x |
| P/E ratio 2023 |
-8.14
x | P/E ratio 2024 * |
-6.2
x | Employees | 177 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 86.36% |
More Fundamentals
* Assessed data
More news
Latest transcript on Hua Medicine (Shanghai) Ltd.
More press releases
| 1 day | +3.14% | ||
| 1 week | +9.33% | ||
| Current month | +11.56% | ||
| 1 month | +7.19% | ||
| 3 months | -12.77% | ||
| 6 months | +8.61% | ||
| Current year | -16.75% |
1 week
1.48
1.68
1 month
1.291.73
Current year
1.292.55
1 year
1.293.12
3 years
1.295.38
5 years
1.299.00
10 years
1.299.00
| Managers | Title | Age | Since |
|---|---|---|---|
Li Chen
FOU | Founder | 61 | 09-11-09 |
Li Changhong
CTO | Chief Tech/Sci/R&D Officer | 55 | - |
Di Hong
COO | Chief Operating Officer | 45 | 21-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Robert Nelsen
CHM | Chairman | 60 | 10-04-22 |
William Keller
BRD | Director/Board Member | 75 | - |
Yiu Wa Tsui
BRD | Director/Board Member | 74 | 18-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.66% | 4 M€ | -27.92% | ||
| 0.00% | 117 M€ | +0.16% | - | |
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 1.62 | +1.89% | 1 256 217 |
| 24-04-25 | 1.59 | 0.00% | 147,000 |
| 24-04-24 | 1.59 | 0.00% | 1,242,500 |
| 24-04-23 | 1.59 | 0.00% | 206,000 |
| 24-04-22 | 1.59 | +6.00% | 526,500 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 02:58 am EDT
More quotes
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Calendar
2024-06-26
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.471
CNY
Average target price
3.072
CNY
Spread / Average Target
+108.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.75% | 199M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.52% | 22.02B | |
| -17.84% | 20.9B | |
| -10.21% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- 2552 Stock
